DMT Stock Overview
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Small Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.15 |
| 52 Week High | CA$0.21 |
| 52 Week Low | CA$0.06 |
| Beta | 0.86 |
| 1 Month Change | -11.76% |
| 3 Month Change | 114.29% |
| 1 Year Change | -9.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.33% |
Recent News & Updates
Shareholder Returns
| DMT | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -6.3% | -1.8% | -0.6% |
| 1Y | -9.1% | 50.8% | 3.9% |
Return vs Industry: DMT exceeded the Canadian Pharmaceuticals industry which returned -32.9% over the past year.
Return vs Market: DMT underperformed the Canadian Market which returned -0.8% over the past year.
Price Volatility
| DMT volatility | |
|---|---|
| DMT Average Weekly Movement | 20.3% |
| Pharmaceuticals Industry Average Movement | 13.9% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: DMT's share price has been volatile over the past 3 months.
Volatility Over Time: DMT's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | George Tziras | www.smallpharma.com |
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company’s product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Small Pharma Inc. Fundamentals Summary
| DMT fundamental statistics | |
|---|---|
| Market cap | CA$50.37m |
| Earnings (TTM) | -CA$19.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs DMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMT income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$19.31m |
| Earnings | -CA$19.31m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DMT perform over the long term?
See historical performance and comparison